288 related articles for article (PubMed ID: 32897326)
1. Drug Repurposing Study Pinpoints Potential COVID-19 Antivirals.
Abbasi J
JAMA; 2020 Sep; 324(10):928. PubMed ID: 32897326
[No Abstract] [Full Text] [Related]
2. Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection.
Clementi N; Ferrarese R; Criscuolo E; Diotti RA; Castelli M; Scagnolari C; Burioni R; Antonelli G; Clementi M; Mancini N
J Infect Dis; 2020 Aug; 222(5):722-725. PubMed ID: 32559285
[TBL] [Abstract][Full Text] [Related]
3. Uncertainty about the Efficacy of Remdesivir on COVID-19.
Yoo JH
J Korean Med Sci; 2020 Jun; 35(23):e221. PubMed ID: 32537956
[No Abstract] [Full Text] [Related]
4. Imatinib is not a potent anti-SARS-CoV-2 drug.
Zhao H; Mendenhall M; Deininger MW
Leukemia; 2020 Nov; 34(11):3085-3087. PubMed ID: 32999432
[No Abstract] [Full Text] [Related]
5. Drug Discovery Strategies for SARS-CoV-2.
Shyr ZA; Gorshkov K; Chen CZ; Zheng W
J Pharmacol Exp Ther; 2020 Oct; 375(1):127-138. PubMed ID: 32723801
[TBL] [Abstract][Full Text] [Related]
6. Cationic drugs and COVID-19.
Brenna OV; Torretta S; Pignataro L; Di Berardino F
Int J Immunopathol Pharmacol; 2020; 34():2058738420966078. PubMed ID: 33045858
[TBL] [Abstract][Full Text] [Related]
7. Rapid repurposing of drugs for COVID-19.
Guy RK; DiPaola RS; Romanelli F; Dutch RE
Science; 2020 May; 368(6493):829-830. PubMed ID: 32385101
[No Abstract] [Full Text] [Related]
8. COVID-19: A Defining Moment for Clinical Pharmacology?
van der Graaf PH; Giacomini KM
Clin Pharmacol Ther; 2020 Jul; 108(1):11-15. PubMed ID: 32350861
[No Abstract] [Full Text] [Related]
9. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
10. Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?
Carradori S
Antiinflamm Antiallergy Agents Med Chem; 2020; 19(2):85-87. PubMed ID: 32213152
[No Abstract] [Full Text] [Related]
11. Repurposing old drugs as antiviral agents for coronaviruses.
Yang CW; Peng TT; Hsu HY; Lee YZ; Wu SH; Lin WH; Ke YY; Hsu TA; Yeh TK; Huang WZ; Lin JH; Sytwu HK; Chen CT; Lee SJ
Biomed J; 2020 Aug; 43(4):368-374. PubMed ID: 32563698
[TBL] [Abstract][Full Text] [Related]
12. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
13. COVID-19: Small-Molecule Clinical Trials Landscape.
Ferreira LLG; Andricopulo AD
Curr Top Med Chem; 2020; 20(18):1577-1580. PubMed ID: 32862824
[No Abstract] [Full Text] [Related]
14. Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?
Severa M; Farina C; Salvetti M; Coccia EM
Front Immunol; 2020; 11():1459. PubMed ID: 32655578
[No Abstract] [Full Text] [Related]
15. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Martinez MA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 RNA polymerase as target for antiviral therapy.
Buonaguro L; Tagliamonte M; Tornesello ML; Buonaguro FM
J Transl Med; 2020 May; 18(1):185. PubMed ID: 32370758
[TBL] [Abstract][Full Text] [Related]
17. Existing Drugs Might Treat COVID-19.
Abbasi J
JAMA; 2020 Jun; 323(22):2239. PubMed ID: 32515802
[No Abstract] [Full Text] [Related]
18. Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.
Santos J; Brierley S; Gandhi MJ; Cohen MA; Moschella PC; Declan ABL
Viruses; 2020 Jun; 12(7):. PubMed ID: 32629804
[TBL] [Abstract][Full Text] [Related]
19. Current Perspective of Antiviral Strategies against COVID-19.
Ahidjo BA; Loe MWC; Ng YL; Mok CK; Chu JJH
ACS Infect Dis; 2020 Jul; 6(7):1624-1634. PubMed ID: 32485102
[TBL] [Abstract][Full Text] [Related]
20. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
Xiong R; Zhang L; Li S; Sun Y; Ding M; Wang Y; Zhao Y; Wu Y; Shang W; Jiang X; Shan J; Shen Z; Tong Y; Xu L; Chen Y; Liu Y; Zou G; Lavillete D; Zhao Z; Wang R; Zhu L; Xiao G; Lan K; Li H; Xu K
Protein Cell; 2020 Oct; 11(10):723-739. PubMed ID: 32754890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
